Background: Readmission within 30 days after hospitalization for heart failure (HF) is a major public health problem.
H eart failure (HF) poses a substantial health and economic burden nationally and is expected to grow significantly in the next 2 decades in the United States. 1, 2 Improving the efficiency and effectiveness of HF care after hospitalization has been a major focus among payers and policy makers to reduce HF-related costs and morbidity. Among Medicare patients hospitalized for HF, >20% are readmitted within 30 days and the most common reason for rehospitalization is HF. 3, 4 A significant fraction of readmissions after HF hospitalizations are seen as preventable given substantial hospital-level variation in readmission rates that are not explained by differences in patient characteristics. 5 In 2013, the Centers for Medicare and Medicaid Services began to penalize hospitals with higher than expected risk-adjusted readmission rates for HF through reduced Medicare payments. 6 Multiple, small randomized studies of post-discharge interventions after hospitalization for HF have reported mixed results, with 2 meta-analyses suggesting possible benefit with various types of interventions, including home visits, clinic visits, and telephone calls. [7] [8] [9] [10] [11] [12] A larger randomized trial in high-risk patients in Canada showed no benefit from a combination of interventions (home visits, clinic appointments, and telephone calls), but the interventions were fragmented from the patients' usual care providers. 13 In contrast, in an observational study relying on clinical registry data linked to administrative claims from hospitals of fee-for-service Medicare beneficiaries, hospitals in the lowest quartile of 1-week post-discharge follow-up rates after HF admissions had the highest 30-day readmission rates. 14 The implications for health systems of implementing a policy focusing on early follow-up strategies are substantial with regards to resource utilization and workflow. To address this, we examined a large, contemporary cohort of adults hospitalized with HF who were carefully characterized longitudinally through a comprehensive electronic health record within an integrated health care delivery system to explore the association between different post-discharge outpatient HF management strategies and the risks of readmission at 30 days.
METHODS

Study Participants
The study was conducted within Kaiser Permanente Northern California, a large, integrated health care delivery system that provides comprehensive care to >3.7 million members within the San Francisco Bay Area. Its membership is highly representative of the local surrounding and statewide population, except for slightly lower representation at the extremes of age and income. 15, 16 We included subjects hospitalized from January 1, 2006 through June 30, 2013 with a primary discharge diagnosis of HF [International Classification of Diseases, Ninth Edition (ICD-9) codes 398.91, 402.01, 402.11, 402.91, 428.0, 428.1, or 428.9], which has been shown to have a positive predictive value of >95% for clinical HF. 17 We excluded patients who died during their index hospitalization or who were discharged to a location other than their home (eg, skilled nursing facility or hospice facility). Patients on chronic dialysis or discharged to home hospice were also excluded, because these groups had structured, predetermined outpatient contact schedules.
Post-discharge Follow-up Patterns
The main exposure of interest was the frequency, timing, and type of follow-up within the first 30 days postdischarge. Relevant post-discharge follow-up was defined as outpatient, non-emergency department telephone calls or clinic visits with internal medicine, family medicine, or cardiology providers. Visits to providers outside of these specialties were excluded because they were unlikely to have been directly involved in HF management. Urgent care and emergency department visits were also excluded because these contacts were likely due to clinical deterioration instead of planned follow-up after hospitalization.
The initial patient contact after hospital discharge was used to categorize follow-up as either in clinic or by telephone. Providers conducting telephone calls were trained to monitor patient symptoms, vital signs, and weights recorded at home; initiate, discontinue, or change medications; request laboratory and other diagnostic testing; and schedule inperson clinic visits. There was no ability to see the patient or conduct a physical examination through a telephone visit. Non-physician providers conducting telephone calls included nurses and pharmacists who were trained to follow an outpatient HF treatment protocol. Non-physician providers may or may not have previously known the patient before hospital discharge. Internal medicine and cardiology physicians following up with patients generally were familiar with the patient before hospital discharge. Outpatient contacts that only involved diagnostic testing, such as electrocardiograms, echocardiograms, or radiologic studies, were also excluded. Finally, visits that only occurred for a specific procedure, such as a vaccination or an infusion, were also excluded.
The timing of the first post-discharge follow-up, the number of post-discharge telephone calls and clinic visits within 30 days, and clinic versus telephone contact were used to characterize the type of post-discharge follow-up each patient received. The timing of the first post-discharge follow-up was categorized as within 1-7 days, 8-30 days, or no follow-up within 30 days after discharge. Follow-up within 7 days was selected because a prior study suggested that follow-up in this early time period could be beneficial for reducing readmissions. 14 The number of post-discharge contacts was calculated by counting the number of outpatient contacts meeting the above criteria.
Outcomes
The primary outcome of interest was all-cause readmission within 30 days of index hospital discharge. All-cause readmissions at health plan-owned and outside facilities were defined as any inpatient admission after discharge from the index hospitalization, excluding emergency department visits not resulting in admission, and were identified from comprehensive hospital discharge and billing claims databases. The health plan billing claims databases are highly reliable for detecting the small fraction of hospitalizations outside of plan-owned facilities. Censoring due to death or disenrollment from the health plan was also ascertained. Deaths were comprehensively identified from Kaiser Permanente hospitalization files, administrative records (eg, proxy reporting), California state death certificate files, 18 and Social Security Administrative vital status files. 19 
Covariates
Age, sex, self-reported race/ethnicity, and censusbased estimates of graduation from high school and of annual household income above $35,000 were identified from health plan databases. We also controlled for the calendar year of index hospitalization for HF. We ascertained information on coexisting illnesses based on diagnoses or procedures using ICD-9 codes, laboratory results, or specific therapies from health plan hospitalization discharge, ambulatory visit, laboratory, and pharmacy databases; diabetes mellitus registry 20 ; and regional cancer registry. 21 The baseline diagnoses were determined at the time of admission for the index HF hospitalization, which included acute myocardial infarction, unstable angina, stroke, prior coronary bypass graft surgery, prior percutaneous coronary intervention, ventricular tachycardia or fibrillation, atrial fibrillation or flutter, implantable cardioverter defibrillator placement, permanent pacemaker implantation, diabetes mellitus, hypertension, systemic cancer, chronic liver disease, chronic lung disease, mitral or aortic valvular disease, dementia, and depression. Left ventricular (LV) systolic function was determined from review of relevant diagnostic test results found in the electronic medical record surrounding the index date. LV systolic function was classified into 1 of 4 categories: normal or hyperdynamic (LV ejection fraction Z50%), mild LV systolic dysfunction (LV ejection fraction 40%-49%), moderate LV systolic dysfunction (LV ejection fraction 30%-39%), or severe LV systolic dysfunction (LV ejection fraction <30%).
Baseline and time-updated laboratory measurements of estimated glomerular filtration rate, serum potassium level, and hemoglobin level were ascertained. Estimated glomerular filtration rate (eGFR, mL/min/1.73 m 2 ) was calculated using the CKD-EPI equation 22 based on ambulatory, nonemergency department serum creatinine measurements. The outpatient, non-emergency department laboratory values closest in time before the index HF hospitalizations were used to determine baseline laboratory values. Time-varying values of laboratory results were ascertained throughout the follow-up period using health plan laboratory databases. A laboratory test was defined as any outpatient test for serum creatinine level, serum potassium level, hemoglobin, or Btype natriuretic peptide.
We also controlled for outpatient receipt of b-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, hydralazine, nitrates, loop diuretics, thiazide diuretics, potassium supplementation, digoxin, and calcium channel blockers based on dispensing found in ambulatory pharmacy databases. Baseline medication use was determined at the time of admission for the index HF hospitalization. As described previously, 23 longitudinal medication use was estimated from drug refill patterns using the calculated day supply for each prescription. We also adjusted for the number of changes in HF medication (defined above) and laboratory tests completed during the follow-up period, as these processes of care may be markers of illness severity. A change in HF medication was defined as addition, discontinuation, or change in dose.
To account for the severity of illness during the index hospitalization, we also adjusted for the hospital length of stay and a validated laboratory-based acute physiology (LAP) score. 24 Statistical models that used the combination of the LAP score and a comorbidity score to estimate inpatient mortality and 30-day mortality after admission were validated in a cohort of 409,305 hospitalizations within KPNC from 2002 to 2005. 24 The c-statistic for the model estimating inpatient mortality was 0.88, whereas that for 30day mortality was 0.86. The LAP score was calculated from serum albumin; anion gap; arterial pH, PaCO 2 , and PaO 2 ; bicarbonate; total serum bilirubin; blood urea nitrogen; serum creatinine; serum glucose; serum sodium; serum troponin I; hematocrit; and total white blood cell count. Eligible laboratory test results were those obtained in the 24-hour time frame preceding hospitalization.
Statistical Analysis
Analyses were performed using SAS software, version 9.3 (SAS Institute Inc., Cary, NC). Baseline characteristics at the time of admission for the index HF hospitalization are presented as means with SDs and frequencies with percentages. Crude readmission rates within 30 days were calculated for each category of post-discharge outpatient followup. Each type of follow-up was compared with no follow-up within 30 days using the Student t test.
We conducted a nested matched case-control study with conditional logistic regression to examine the independent association between post-discharge follow-up variables and the outcome of all-cause readmission after appropriately addressing potential survivor bias through individual-level matching on duration of available follow-up time among cases and controls to ensure equal opportunity to receive follow-up care. This is critical as patients can receive more follow-up solely due to surviving and not being readmitted to the hospital. For each case, we randomly selected 5 eligible controls that were matched by amount of follow-up time. For example, a patient readmitted 10 days after hospital discharge would be considered a case. All patients who had not been readmitted by the 10th day of follow-up would then be eligible to be a control for this particular case. Cases and their controls matched by follow-up time from hospital discharge would have equal opportunity to receive follow-up care. In addition, for patients with a hospital readmission, only eligible outpatient contacts before the first readmission were analyzed in the regression models for readmission as an outcome. Because death precludes readmission, there is the possibility that higher rates of death could lead to lower rates of readmission. Therefore, patients who died within 30 days of discharge without a readmission were excluded from the all-cause readmission analysis to address this possible effect of competing risk between death and readmission. Finally, missing laboratory and LVEF data were assigned to a separate "missing" category.
Three separate conditional logistic regression models were created, 1 for each exposure of interest: frequency, timing, and type of follow-up. These exposures were not included in the same model because there was significant correlation between them. For each regression model, all the covariates described previously were used to adjust for residual differences between patients.
RESULTS
Study Sample and Patient Characteristics
We identified 11,985 eligible adults who were hospitalized for HF between January 1, 2006 and June 30, 2013, who were not receiving chronic dialysis, and who were discharged to home without hospice care. From this eligible study population, we identified 1587 cases who were readmitted to the hospital within the first 30 days post-discharge. These cases were then matched with 7935 eligible controls individually matched on having the same follow-up time as the corresponding case. Case patients were significantly older and had more comorbidities than control patients, including being more likely to have a HF hospitalization in the prior year, a history of myocardial infarction, atrial fibrillation or flutter, valvular disease, diabetes, depression, dementia, lung disease, cancer, chronic kidney disease, and anemia (Table 1) . , which is associated with a predicted in-hospital mortality risk of between 1% and 5%. 25 The timing, number, and types of post-discharge follow-up contacts with a general medicine or cardiology provider are described for cases and controls in Table 2 . Overall, about 70% of patients had either a clinic visit or a telephone call within 30 days of hospital discharge, with about 50% having contact within the first 7 days. The majority (84%) of the follow-up contacts were clinic visits, as opposed to telephone calls (16%). Almost all (94%) clinic visits were with physicians, whereas 45% of the telephone calls were made by non-physician providers. There was no significant difference in 30-day follow-up between cases and controls (70% vs. 72%, P = 0.10). However, cases were less likely to have follow-up within 7 days compared with controls (50% vs. 53%, P = 0.01).
Crude Readmission Rates
The overall 30-day readmission rate for the study cohort was 13.2%, with an overall 30-day mortality rate of 3.0%. Crude rates of 30-day readmission stratified by followup timing, number, and type are shown in Figure 1 . Any follow-up, regardless of timing, number, and type, was associated with a significantly lower crude risk of readmission within 30 days of discharge (P < 0.01).
Associations of Follow-up Characteristics and 30-Day Readmission
In matched case-control analyses, follow-up within 7 days post-discharge was associated with 19% (95% CI, 6%-30%) lower adjusted odds of readmission (Table 3) after extensive adjustment for comorbidities, hospitalization characteristics, severity of acute illness, laboratory values, baseline HF medication use, and the number of laboratory checks and HF medication changes. Initial contact after 7 days post-discharge was not significantly associated with lower adjusted odds of readmission. Initial contact by clinic visit was associated with a 15% (95% CI, 2%-27%) lower adjusted odds of readmission. Initial contact by telephonefrequently conducted by non-physicians-was associated with lower adjusted odds of 30-day readmission [adjusted odds ratio (OR) = 0.85; 95% CI, 0.69-1.06] but was not statistically significant. The adjusted odds of readmission within 30 days of discharge was lower for 1-2 follow-up contacts compared with no follow-up. Greater than 2 contacts trended toward lower odds of readmission with a similar point estimate, but did not meet statistical significance. The detailed regression model results are available for viewing online (Tables, Supplemental Digital 
DISCUSSION
Within a large, diverse integrated health care delivery system, we found that the timing of initial follow-up was a significant factor affecting the odds of readmission in a contemporary sample of mostly older adults discharged following hospitalization for acute HF. Follow-up within 1 week was independently associated with 19% lower odds of readmission, whereas initial follow-up after 1 week was not significantly associated with readmission. Compared with no follow-up, 1 or 2 total contacts within 30 days of hospital discharge and initial contact by clinic visit were independently associated with lower odds of readmission. Early telephone call follow-up was associated with a trend toward lower 30-day readmission rates.
We systematically explored how various aspects of follow-up (timing, type, and total number) were associated with 30-day readmission. Our study findings extend existing limited evidence that early follow-up within 7 days of hospital discharge is beneficial for preventing readmission in patients with HF. 14 There was no benefit observed with initial contact between 8 and 30 days after discharge compared with no follow-up at all (adjusted OR = 0.99; 95% CI, 0.82-1.19). One novel finding that may warrant further study is that early initial contact by telephone-which was frequently (45%) conducted by non-physician providers (eg, nurses or pharmacists)-had a trend toward decreased odds of 30-day readmission (adjusted OR = 0.85; 95% CI, 0.69-1.06). The point estimate of the OR for initial contact by telephone was the same as for initial contact through a clinic visit. However, the confidence interval was wider, because only 12% of patients had initial contact by telephone, as compared with 60% of patients with initial contact in clinic.
Outside of initial contact 8-30 days after hospital discharge which showed no beneficial association, we observed similar strengths of association between various types of post-discharge follow-up and lower odds of readmission (ORs = 0.81-0.87) compared with a previous observational study. 14 However, our observations were different from various other studies that showed no benefit for postdischarge follow-up. 13, [26] [27] [28] [29] Post-discharge follow-up as observed in our study may have had a greater impact on reducing 30-day readmission compared with these other studies for multiple reasons. Our study was conducted in a fully integrated health care delivery system with a single electronic medical record, compared with other more fragmented systems of care. 13 In addition, only follow-up contacts with internal medicine, family medicine, or cardiology providers were included, as opposed to any type of physician follow-up. 14 General medicine and cardiology providers are more likely to address HF-specific care and post-hospitalization issues that could affect readmission. In our study, patients who were discharged to hospice care or to a nursing facility or receiving chronic dialysis were also excluded, because they were effectively placed in a different system of care that either had different goals of care or did not involve short-term outpatient follow-up. By excluding patients who are predictably near death and placed in hospice care and those discharged to nursing homes, the follow-up interventions advocated by current HF guidelines 30 were likely to be more effective in patients who would be most likely to benefit from them. Systematic follow-up after hospital discharge for HF is generally regarded as likely to reduce readmission and is actively being employed in many hospital systems. 31 However, what is not fully known is how specific aspects of follow-up care, including timing, provider type (ie, nurse, pharmacist, and physician), method of contact (ie, telephone, video, clinic, and in-home), and extent of coordination with other providers, affects the effectiveness of interventions. A systematic review of 21 randomized trials of transitional care, not specifically for HF patients, implied that higher intensity follow-up, specifically with home visits, reduced readmission. 32 However, a recent, significantly larger randomized trial showed that intensive follow-up with combination of home visits, telephone calls, and clinic visits did not show reduction in readmission in high-risk patients. 13 Some major reasons for the lack of benefit, as cited by the authors, were lack of coordination with primary care physicians and incompatibility of electronic medical records.
These study data support that a high degree of care coordination in addition to greater intensity of follow-up may be important for reducing readmission.
With the advent of accountable care organizations and the mandate for meaningful use of the electronic medical record, health care delivery systems in the United States are becoming more integrated and transparent between networks of providers. 33, 34 Our results imply that clinicians may be able to leverage this increasing integration to improve the effectiveness of transitional care and reduce hospital readmissions in high-risk populations. While an initial in-person clinic visit was associated with reduced odds of 30-day readmission, an early initial contact by telephone with a physician or non-physician provider may be more practical to implement by many health care delivery systems compared with clinic visits for all patients. Although we did not show a definitive benefit for initial contact by telephone, this specific finding warrants further investigation.
In an observational study, we cannot completely exclude the possibility of unmeasured confounders and residual treatment selection bias, despite our ability to adjust for a large number of individual-level patient and hospitalization characteristics and use of individual-level matching to account for differential follow-up time among patients. Differences in disease severity or other patient characteristics could have led to a higher or lower likelihood of both early follow-up and readmission. Indeed, we observed that cases tended to be more ill than the controls, as measured by age and comorbid conditions, and that adjustment for these differences strengthened the association between early followup and lower odds of readmission. In addition, the study was conducted within an integrated health care system with a comprehensive electronic medical record, which could have potentiated the observed benefit of outpatient follow-up. Our findings may not be fully generalizable to other practice settings with less transparency and coordination of care between hospital and outpatient locations. Data regarding LV systolic function was unavailable for approximately a third of the study cohort, so we were unable to evaluate potential effect modification of follow-up patterns and LV systolic function on 30-day outcomes.
In conclusion, early in-person clinic follow-up with general medicine or cardiology providers within 7 days after a HF hospitalization was independently associated with lower odds of readmission within 30 days. Initial contact with telephone calls-nearly half being conducted by nonphysicians-showed a trend toward lower odds of readmission. Our study provides strong evidence that systematic, early in-person clinic follow-up after HF hospitalization could decrease 30-day readmission. Early telephone followup, which is easier for patients and health care providers, may also offer similar benefit as an in-person clinic visit. *Covariates included age, sex, race/ethnicity, annual household income, graduation from high school, hypertension, diabetes, myocardial infarction, unstable angina, coronary artery bypass graft surgery, percutaneous coronary intervention, atrial fibrillation/flutter, ventricular tachycardia/fibrillation, mitral/aortic valvular disease, depression, dementia, chronic lung disease, chronic liver disease, cancer, permanent pacemaker, implantable cardioverter defibrillator, hospitalization for stroke or transient ischemic attack, hospitalization for heart failure within the prior year, left ventricular ejection fraction category, estimated glomerular filtration rate, serum potassium, hemoglobin, cardiovascular medication use (angiotensin-converting enzyme inhibitor, angiotensin II receptor blockers, b-blocker, loop diuretic, thiazide diuretic, potassium supplementation, calcium channel blocker, digoxin, nitrates, and hydralazine), and the number of laboratory checks and heart failure medication changes during follow-up.
Bold indicates the statistically significant findings.
